[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongshan Ophthalmic Center, Sun Yat-sen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,42,84,112,144,166,193,214,245,268,286,307,329,350,374,393,411,440,456,478,500,523,544,563,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643713","the-effect-of-eyelid-support-plate-assisted-eyelid-massage-on-meibomian-gland-dysfunction-a-randomized-controlled-trial-100643713",false,"NCT07633938","The Effect of Eyelid Support Plate Assisted Eyelid Massage on Meibomian Gland Dysfunction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily participate and sign an informed consent form;\n2. Age range: 18 to 60 years old;\n3. Meet the diagnostic criteria for dry eye in the International Society of Tears and Ocular Surface (TFOS) Dry Eye Symposium (DEWS) II ;\n4. 1\u002F3 or more of the meibomian gland openings are blocked or the secretion characteristics of the meibomian gland are abnormal;\n5. The best corrected visual acuity for each eye is ≥ 0.5;\n6. Eye pressure (IOP) ≥ 5mmHg and ≤ 21mmHg per eye;\n7. Women with reproductive potential agree to use reliable contraceptive methods during the study period;\n8. Willing and able to complete all planned research visits and follow the guidance of the researchers.\n\nExclusion Criteria:\n\n1. Contact lens use: Having used contact lenses within 14 days prior to the screening visit, or refusing to commit to discontinuing contact lens use during the study period (within the next 2 months);\n2. Had undergone corneal refractive surgery (e.g., LASIK\u002FSMILE), other corneal surgeries, cataract surgery, anti-glaucoma surgery, or fundoscopic surgery within 12 months prior to enrollment screening;\n3. Participation in other medical studies within 3 months prior to enrollment screening;\n4. Presence of any of the following active ocular diseases at present or within 3 months prior to screening: I) Acute allergic conjunctivitis; II) Infection (by bacteria, viruses, fungi, etc.); III) Inflammation (e.g., keratitis, retinitis).\n\n   Meningitis, choroiditis, uveitis, scleritis, etc.;\n5. Eyelid abnormalities affecting eyelid function (such as ptosis, blepharospasm, entropion, ectropion, etc.);\n6. Extensive ocular surface scars or conditions that may compromise ocular surface integrity (e.g., Stevens-Johnson syndrome, history of chemical burns, persistent corneal epithelial defects, history of ocular trauma, etc.);\n7. Currently or previously diagnosed with glaucoma, or undergoing treatment with anti-glaucoma medications;\n8. Has used any of the following ocular medications within the past 1 month: immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or perfluorohexyloctane;\n9. Has received any of the following non-pharmacological treatments for dry eye within the past month: meibomian gland massage, deep eyelid margin cleansing, intense pulsed light therapy, or thermal pulsation therapy;\n10. During pregnancy or lactation;\n11. Neurological or psychiatric disorders (moderate to severe anxiety, depression, and sleep disorders);\n12. Uncontrolled ocular or systemic diseases;\n13. History of epilepsy;\n14. The investigator determines that the subject is not suitable for participation in this study.","ALL","18 Years","60 Years",{"count":20,"type":21},142,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to conduct a randomized controlled clinical trial to compare the efficacy of a new type of massage device - eyelid support plate and glass rod assisted eyelid massage in improving MGD related dry eye symptoms, and evaluate the comfort and efficiency of both treatments, providing evidence-based support for clinical work",[27,28],"Dry Eye Disease (DED)","MGD-Meibomian Gland Dysfunction","NOT_YET_RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":21},"2026-07-01",{"date":37,"type":21},"2027-09-01",{"name":39,"class":40},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":41},"100643686","development-of-a-mobile-terminal-based-intelligent-detection-system-for-multiple-anterior-segment-diseases-of-the-eye-100643686","NCT07634913","Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye","LENS","Inclusion Criteria:\n\n* Adults aged 18 years or older;\n* Willing to participate and able to provide written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Unable to cooperate with anterior segment image capture (including smartphone-based photography or slit-lamp biomicroscopy).",true,{"count":51,"type":21},3000,"OBSERVATIONAL","This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening. The system is designed to identify 16 clinically important anterior segment conditions from images captured using a standard Android smartphone. A core design feature of the system is that all image analysis is performed entirely on the smartphone itself, without requiring internet connectivity or cloud-based server infrastructure.\n\nThe study is motivated by a structural challenge in the deployment of medical AI: systems that depend on cloud infrastructure for inference are non-functional in settings without reliable internet access, which disproportionately excludes populations in low-resource regions where the burden of preventable eye disease is highest. This study evaluates whether an on-device AI system, designed with operational constraints as a primary engineering objective, can deliver clinically acceptable diagnostic performance while remaining operable under real-world connectivity limitations.\n\nThe study comprises five evaluation components. First, the diagnostic performance of the AI system is benchmarked against board-certified ophthalmologists of varying seniority on a standardized set of smartphone-captured anterior segment images. Second, the usability of the system is evaluated among non-medical users who perform self-administered screening with minimal instruction, with per-screening time recorded across consecutive attempts to characterize the learning curve. Third, a head-to-head field trial directly compares the on-device AI system against a functionally equivalent cloud-based deployment of the same model architecture across key operational dimensions including screening duration, diagnostic performance, and user acceptability. Fourth, population-level screening is conducted among consecutively enrolled community residents at two low-resource sites, with per-disease sensitivity and specificity calculated against reference-standard slit-lamp examinations. Fifth, pre-specified health-economic and environmental analyses compare the two deployment modalities in terms of per-person screening cost, cost-effectiveness, per-inference electricity consumption, and projected carbon emissions at scale.\n\nThe reference standard for all diagnostic comparisons is slit-lamp biomicroscopic examination performed by board-certified ophthalmologists. The study is designed and reported in accordance with the DECIDE-AI reporting guideline for early-stage clinical evaluation of AI-driven decision-support systems.",[55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70],"Artifical Intelligence","Cataract","Pterygium","Keratopathy","Subconjunctival Hemorrhage","Conjunctivitis","Stye","Blepharitis","Entropion","Ectropion","Exophthalmos","Irregular Pupils","Conjunctival Concretions","Hyphema","Hypopyon","Corneal Transplant Status",[72,73,74,75],"Artificial Intelligence","Standalone Deployment","Smartphone","Eye Disease Screening","RECRUITING",{"date":78,"type":33},"2026-06-09",{"date":80,"type":33},"2023-12-12",{"date":82,"type":21},"2028-12",{"name":39,"class":40},{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":49,"sex":16,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":95,"studyType":52,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":41},"100504665","the-proactive-ophthalmic-examination-cohort-100504665","NCT05851287","The Proactive Ophthalmic Examination Cohort","The Proactive Ophthalmic Examination Cohort of Older Adults","POEC","Inclusion Criteria:\n\n\\- Aged 65 years or older\n\nExclusion Criteria:\n\n* Unable to complete required systemic or ophthalmic examinations due to frailty, poor general health, or other physical limitations\n* Refusal to participate in the study","65 Years",{"count":94,"type":21},5000,"10 Years","The Proactive Ophthalmic Examination Cohort of Older Adults is a prospective cohort study recruiting community-dwelling older adults aged 65 years or older. Through comprehensive assessment of demographic profiles, medical histories, and ocular structural and functional parameters, alongside systematic collection of ophthalmic and systemic clinical data and biological specimens, we will establish a multidimensional, high-quality ocular health database encompassing demographic characteristics, socioeconomic factors, lifestyle variables, ocular disease risk factors, subjective ocular symptoms, objective examination findings, and biospecimens. The study will investigate the onset and progression patterns of ocular diseases, associated risk factors, and mechanisms of ocular aging in older populations, while simultaneously providing normal-controlled clinical and genomic data for other clinical studies on eye diseases. Furthermore, leveraging algorithmic innovation and artificial intelligence technologies, we will develop a personalized risk prediction and monitoring platform for age-related eye diseases, enhancing early screening and diagnostic capabilities and advancing precision medicine for ocular health in older adults.",[98,99],"Vision Impairment","Eye Diseases",[101,102,103,104,105],"older adults","eye health","cohort","risk factor","eye diseases",{"date":78,"type":33},{"date":108,"type":33},"2023-02-20",{"date":110,"type":21},"2034-02-19",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100563021","home--vs-hospital-based-care-of-anti-vegf-treatment-for-diabetic-macular-edema-non-inferiority-rct-100563021","NCT06610747","Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT","Home Care Monitoring of Visual Acuity and OCT Versus Standard Hospital\u002FClinic Care Monitoring During Diabetic Macular Edema Management: A Non-inferiority Randomized Clinical Trial","DME HOME","Participant-level Criteria:\n\nInclusion Criteria:\n\nTo be eligible, the following inclusion criteria must be met:\n\n* Age of 18 years or older;\n* Type 1 or type 2 diabetes mellitus\n* Current regular use of insulin for the treatment of diabetes or current regular use of oral anti-hyperglycemia agents for the treatment of diabetes\n* Travel time from home to the hospital\u002Fclinic within a 2-hour driving distance\n* At least one eye meets the study eye criteria listed in Section 2.4\n* Ability and willingness to operate the self-administrated visual acuity tester and Home OCT device by themselves or with the help of family after training\n* Ability and willingness to provide informed consent\n\nExclusion Criteria:\n\nAn individual is not eligible if any of the following exclusion criteria are present:\n\n* Conditions that would preclude participation in the study, such as unstable medical status including blood pressure, cardiovascular disease, renal disease, and glycemic control as determined by the investigators\n* History of systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization. These drugs should not be used during the study;\n* In an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied\n* Blood pressure \\> 180\u002F110 (systolic above 180 or diastolic above 110. If blood pressure is brought below 180\u002F110 by anti-hypertensive treatment, then the individual may be eligible\n* History of myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months before enrollment\n* For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 2 years. Women who are potential study participants should be questioned about the potential for pregnancy, and the investigator will determine when a pregnancy test is needed\n* Currently participating in other clinical trials\n* The individual who might move out to an area beyond 2-hour driving distance during the first 12 months of the study\n\nStudy eye-level Criteria:\n\nThe participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below. Participants can have only one study eye. If both eyes are eligible at the time of enrollment and one of the eyes has never received anti-VEGF treatment, that eye should be included. If both eyes are eligible and have previously received anti-VEGF treatment or both eyes have never received anti-VEGF, then the better-seeing eye will be selected before enrollment. If neither eligible eye is the better-seeing eye, then the investigator and participant will select the study eye by mutual agreement before enrollment.The definition of better-seeing, worse-seeing and same eye is in the followings:\n\n* If the baseline visual acuity letter score in both eyes is 50 (20\u002F100) or better, the better-seeing eye is the eye with better baseline visual acuity (better than that of the fellow eye by 5 letters or more), and the worse-seeing eye is the eye with worse baseline visual acuity (worse than that of the fellow eye by 5 letters or more); if the baseline visual acuity of one eye is within 4 letters of that of the fellow eye, the two eyes are the same and neither eye is the better-seeing eye.\n* If the baseline visual acuity letter score in both eyes is \\< 50 (20\u002F100), the better-seeing eye is the eye with better baseline visual acuity (better than that of the fellow eye by 10 letters or more), and the worse-seeing eye is the eye with worse baseline visual acuity (worse than that of the fellow eye by 10 letters or more); if the baseline visual acuity of study eye is within 9 letters of that of the fellow eye, the two eyes are the same and neither eye is the better-seeing eye.\n\nThe eligibility criteria for a study eye are as follows:\n\nInclusion Criteria:\n\n* Central-involved DME (central subfield thickness on OCT defined on Heidelberg Spectralis OCT 320 μm or more in men and 305 μm or more in women, or Zeiss Cirrus OCT 305 μm or more in men and 290 μm or more in women, or the equivalent on spectral-domain OCT based on gender specific cutoffs)\n* Best corrected visual acuity letter score ≤ 78 (i.e., 20\u002F32 or worse) and ≥ 24 (i.e., 20\u002F320 or better) within seven days of inclusion\n* Received no treatment for DME before, or received no anti-VEGF injection for DME within the past 3 months; however, if there is a history of anti-VEGF injections, \\\u003C=1 injection in the past year and \\\u003C=3 injections over the study participant's lifetime); or, \\\u003C=2 monthly injections within the past 3 months and \\\u003C=3 injections over the past year, and \\\u003C=6 injections over the study participant's lifetime.\n* Sufficient media clarity, pupillary dilation, and individual cooperation to allow for adequate fundus photographs and adequate OCT\n\nExclusion Criteria:\n\nThe following exclusions apply to the study eye only (i.e., they may be present for the non-study eye):\n\n* Macular edema due to reasons other than diabetes\n* Any history of prior laser, other surgical or corticosteroid treatment for DME (such as focal\u002Fgrid macular photocoagulation, intravitreal corticosteroids or peribulbar corticosteroids) within the prior 12 months\n* History of intravitreal anti-VEGF for an ocular condition other than DME (e.g., choroidal neovascularization, central retinal vein occlusion, PDR) within the prior 6 months or anticipated need in the next 6 months\n* Coexisting ocular diseases that might alter visual acuity during the course of the study, such as a retinal vein or artery occlusion, uveitis or other ocular inflammatory diseases, neovascular glaucoma, etc.\n* A substantial cataract that, in the investigator's opinion, is likely to be decreasing visual acuity by 3 lines or more. This means that the cataract would be reducing acuity to 20\u002F40 or worse if the eye were otherwise normal\n* History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckling, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization\n* Uncontrolled glaucoma\n* Severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis.",{"count":121,"type":21},308,[24],"Diabetic macular edema (DME) is a common cause of central visual loss in diabetic patients and a global public health burden around the world. Most patients with DME and vision loss require pharmacological inhibition using anti-VEGF agents with multiple monitoring visits that require both visual acuity testing and optical coherence tomography (OCT) to determine if re-treatment is warranted as well as the recommended time interval to the next follow-up visit. However, this treatment regimen often requires monthly or every other month clinic visits, which places a substantial burden on ophthalmic clinics and patients.\n\nRecently, portable self-administered Home OCT devices have been developed that allow for home-based OCT scanning of retinal diseases, e.g., DME, although these devices do not include visual acuity determination. The investigators previously proposed to deliver Home OCT devices and Home visual acuity tester to patients\\' homes to complete routine monitoring visits at home. However, there is a lack of evidence regarding the safety and efficacy of this novel monitoring regimen for DME patients, specifically whether its use could reduce the burden associated with frequent hospital visits without sacrificing visual acuity outcomes.\n\nThis study aims to provide evidence to support use of a novel monitoring regimen for DME patients that could substantially reduce the burden associated with frequent hospital visits without sacrificing visual acuity outcomes.",[125],"Diabetic Macular Edema",[127,128,129,130,131,132,133,134,135],"Diabetic macular edema","Diabetic retinopathy","Aflibercept","Anti-VEGF","Home care monitoring","Home OCT","Best-corrected visual acuity","Visit burden","Randomized clinical trial","2026-06-05",{"date":30,"type":33},{"date":139,"type":33},"2024-10-28",{"date":141,"type":21},"2027-04-30",{"name":39,"class":40},4,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":12,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":154,"studyType":52,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100635301","the-impact-of-surgical-procedures-on-postoperative-outcomes-in-cataract-phacoemulsification-and-analysis-of-related-factors-100635301","NCT07550907","The Impact of Surgical Procedures on Postoperative Outcomes in Cataract Phacoemulsification and Analysis of Related Factors","Inclusion Criteria:\n\n* Age ≥ 50 years and ≤ 90 years\n* Diagnosis of unilateral\u002Fbilateral age-related cataract\n* Nuclear grade ≥2 in LOCSIII classification\n* Scheduled for cataract phacoemulsification combined with intraocular lens implantation\n* Pupil size ≥6mm after dilation\n* Corneal endothelial cell count ≥1500 cells\u002Fmm²\n\nExclusion Criteria:\n\n* Diagnosis of severe systemic disease (e.g., severe hypertension or Alzheimer's disease)\n* History of ocular trauma or surgery\n* Presence of other ocular diseases (such as glaucoma, diabetic retinopathy, or high myopia)\n* Other ocular factors that may complicate the surgery (such as small pupil, shallow anterior chamber)","50 Years","90 Years",{"count":153,"type":21},300,"1 Month","The goal of this observational study is to evaluate the location of phacoemulsification tip measured by intraoperative OCT during cataract surgeries and its impact on early postoperative changes of cornea and visual acuity. The main question it aims to answer is:\n\nIn patients with age-related cataracts undergoing phacoemulsification, does the location (supracapsular, iris-lens diaphragm, or endocapsular) of the phaco tip affect postoperative corneal changes and visual acuity at early postoperative stage? Eyes having phacoemulsification for cataracts will receive intraoperative OCT imaging to evaluate the location of the phaco tip during surgery, and corneal changes and visual acuity will be measured postoperatively.",[157],"Age-related Cataract","2026-06-01",{"date":160,"type":33},"2026-06-03",{"date":162,"type":33},"2026-04-20",{"date":164,"type":21},"2027-06-30",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100637750","ai-assisted-structured-guidance-for-narrative-review-writing-100637750","NCT07618819","AI-Assisted Structured Guidance for Narrative Review Writing","Effect of Artificial Intelligence-Assisted Structured Guidance on the Quality of Narrative Literature Reviews Among Medical Postgraduate Students: A Randomized Controlled Educational Study","Inclusion Criteria:\n\n1. Master's students enrolled in the Academic Standards and Thesis Writing course.\n2. Willing to participate in this study, able to understand the study procedures and randomization arrangement, and able to provide written informed consent.\n3. Able to complete literature searching, use AI tools, and complete online questionnaires.\n\nExclusion Criteria:\n\n1. Students who have confirmed withdrawal from the course, suspension of study, long-term leave, or other known objective reasons that prevent participation in subsequent major teaching activities and study procedures.\n2. Students who have participated in pilot testing, intervention material development, assessment training, or data processing related to this study.",{"count":174,"type":21},102,[24],"This randomized, parallel-group, assessor-blinded educational study will evaluate whether one session of AI-assisted structured guidance improves the quality of narrative literature reviews written by medical postgraduate students. A total of 102 students enrolled in an academic writing course will be randomly assigned to either an AI-assisted structured guidance group or a free AI use group. Both groups may use AI tools under academic integrity requirements and will complete a narrative literature review according to the same course requirements. The guidance group will receive one structured guidance session approximately two weeks before final submission. The session will be based on the six dimensions of the Scale for the Assessment of Narrative Review Articles (SANRA). The primary outcome is the final SANRA total score of the submitted narrative literature review.",[178,179,180],"AI-Assisted Academic Writing","Medical Education","Narrative Review Writing",[72,179,182,183,184,185],"Postgraduate Education","Narrative Literature Review","Academic Writing","SANRA","2026-05-25",{"date":158,"type":33},{"date":189,"type":21},"2026-06",{"date":191,"type":21},"2026-09",{"name":39,"class":40},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":151,"enrollmentInfo":199,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":41},"100637940","choroidal-and-retinal-features-in-pacd-and-poag-on-oct-and-octa-100637940","NCT07580014","Choroidal and Retinal Features in PACD and POAG on OCT and OCTA","Inclusion Criteria:\n\n* Control group: Healthy individuals with no history of ocular surgery, IOP \\\u003C 21 mmHg, and CDR \\\u003C 0.5 bilaterally without asymmetry\n* Observation group: Glaucoma specialist-confirmed diagnosis of POAG or PACD (per ISGEO staging: PACS\u002FPAC\u002FPACG)\n\nExclusion Criteria:\n\n* History of retinal or macular disease (e.g., AMD, DR, RVO, ERM)\n* Non-glaucomatous optic neuropathy (e.g., MS, NMO)\n* Poor OCT\u002FOCTA image quality\n* Refusal to sign informed consent",{"count":200,"type":21},132,"Glaucoma is a group of irreversible, progressive optic neuropathies that can lead to severe visual field defects and even blindness, affecting nearly 95 million people worldwide. Based on anterior chamber angle structure, glaucoma is classified into primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG). Although POAG is more common, PACG is more severe and more likely to cause blindness if not managed appropriately. Globally, PACG accounts for approximately 25% of all glaucoma cases but is responsible for roughly 50% of glaucoma-related blindness. Generally, the term \"glaucoma\" implies optic nerve damage; however, glaucomatous optic neuropathy may be absent in subacute and acute angle-closure glaucoma. Therefore, according to international consensus, primary angle-closure disease is categorized as PACD-encompassing primary angle-closure suspect (PACS), primary angle closure (PAC), and PACG-based on the extent of angle closure, intraocular pressure elevation, and optic nerve damage. With advances in ophthalmic imaging, an increasing array of diagnostic modalities has been applied to glaucoma diagnosis. Optical coherence tomography (OCT), which utilizes low-coherence light to display cross-sectional images of the retina in vivo, represents a rapid, non-invasive, and continuously evolving imaging method. Building upon OCT, OCTA has emerged as a novel imaging technique that allows non-invasive visualization and assessment of blood flow in individual retinal layers \\[5\\]. Existing OCT and OCTA research on glaucoma primarily focuses on the optic disc and macula of glaucoma patients, providing evidence of changes in the retinal nerve fiber layer, macular ganglion cell thickness, optic nerve head structure, and peripapillary and macular vasculature. Other studies have examined choroidal vascular architecture and thickness in glaucoma; previous findings from our research group also indicate that choroidal vascular density is significantly lower in eyes with POAG and PACG compared to normal eyes, while choroidal stromal area is significantly greater in PACG than in POAG eyes and normal controls. Further investigation into choroidal and retinal alterations in glaucoma is warranted. Consequently, the OCT and OCTA fundus characteristics of patients with PACD and POAG remain an area with unexplored unknowns. This study utilizes OCT and OCTA to observe the choroidal and retinal tissue structure and vascular hemodynamics in patients with PACD and POAG, aiming to comprehensively investigate structural changes in the glaucomatous fundus, broaden new research directions, and explore and supplement the understanding of glaucoma pathogenesis.",[203,204,205],"Glaucoma","OCTA","Choroid","2026-05-06",{"date":208,"type":33},"2026-05-12",{"date":210,"type":33},"2024-07-16",{"date":212,"type":21},"2027-04-20",{"name":39,"class":40},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":16,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":227,"conditions":228,"keywords":233,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":41},"100639649","phase-4-effective-dose-of-alfentanil-combined-with-propofol-for-laryngeal-mask-airway-insertion-in-children-100639649","NCT07581665","Effective Dose of Alfentanil Combined With Propofol for Laryngeal Mask Airway Insertion in Children","Effective Dose of Alfentanil Combined With Propofol for Laryngeal Mask Airway Insertion in Children: A Prospective, Up-and-Down Sequential Allocation Study","Inclusion Criteria:\n\n* Aged 7 to 12 years\n* Undergoing elective day surgery\n* ASA physical status I-II\n* Body Mass Index (BMI) between 14 and 24 kg\u002Fm²\n* Accompanied by a fully capable guardian within 24 hours after discharge\n\nExclusion Criteria:\n\n* Allergy to opioids\n* Unresolved upper respiratory tract infection within the past 1 week\n* Abnormal heart, lung, liver, or kidney function, or metabolic diseases\n* Airway anatomical abnormalities (e.g., micrognathia, laryngomalacia, macroglossia) or OSAHS (Obstructive Sleep Apnea-Hypopnea Syndrome)\n* Use of analgesics, sedatives, or other psychotropic drugs within the past 2 weeks\n* Refusal to sign the informed consent form","7 Years","12 Years",{"count":224,"type":21},40,[226],"PHASE4","This study uses a prospective, up-and-down sequential allocation method to determine the median effective dose (ED50) and 95% effective dose (ED95) of alfentanil combined with propofol for successful laryngeal mask airway (LMA) insertion in children aged 7-12 undergoing elective day surgery.",[229,230,231,232],"Pediatric Anesthesia","Airway Management","General Anesthesia","LMA",[234,235,229,232,236,237],"Alfentanil","Propofol","Dixon Method","Effective dose","2026-05-05",{"date":208,"type":33},{"date":241,"type":21},"2026-05-01",{"date":243,"type":21},"2027-03-30",{"name":39,"class":40},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":16,"minAge":252,"maxAge":222,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":266,"locationsCount":267},"100600371","efficacy-of-visual-and-perceptual-training-on-visual-function-for-operative-congenital-ectopia-lentis-children-100600371","NCT07096622","Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children","Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children: A Randomized Controlled Clinical Trial","Inclusion Criteria\n\n1. Aged 4-12 years, with no gender restriction;\n2. Diagnosed with congenital ectopia lentis;\n3. Underwent bilateral lensectomy combined with IOL scleral fixation, and within 1 month ± 1 week after the second-eye surgery;\n4. Best-corrected visual acuity (BCVA) of unilateral or bilateral eyes is no worse than 20\u002F200 but below the normal level for the corresponding age: for 4-year-old children, BCVA ≤ 20\u002F40; for children aged 5 years and above, BCVA ≤ 20\u002F30;\n5. Written informed consent signed by the patient and their parents or legal guardians.\n\nExclusion Criteria\n\n1. History of ocular trauma or previous ocular surgery other than the study-related procedure;\n2. Unable to cooperate with treatment, examinations, and follow-up assessments;\n3. Complicated with recurrent lens dislocation, severe cataract (dense, axial, opacity diameter \\>3 mm and affecting central vision), secondary glaucoma, corneal endothelial decompensation, retinal detachment, or other conditions requiring urgent surgical intervention;\n4. Presence of diplopia in either eye;\n5. Known history of neurological disorders (e.g., photosensitive epilepsy);\n6. Participation in other clinical trials within the postoperative period that may affect the outcomes of the present study;\n7. Use of topical or systemic medications that may cause visual impairment, or other vision therapies other than refractive correction in the past 3 months (e.g., atropine penalization, occlusion therapy, digital therapy, Bangerter filters, optical suppression, VR training, etc.).","4 Years",{"count":254,"type":21},82,[24],"This is a multi-centre, open-label, parallel-group randomized controlled trial with the following objectives: Firstly, the investigators aim to evaluate the efficacy of web-based visual and perceptual training therapy on visual function in children with postoperative congenital ectopia lentis. Secondly, the investigators target to investigate the in stereoacuity, quality of life scores, and treatment compliance following visual and perceptual training intervention. Thirdly, to explore the safety profile of visual and perceptual training therapy software in this specific patient population. Lastly, this study aims to provide evidence-based recommendations for visual rehabilitation training strategies in children with postoperative congenital ectopia lentis in the Chinese population.",[258,259],"Ectopia Lentis","Lens Subluxation or Dislocation","2026-04-21",{"date":262,"type":33},"2026-04-27",{"date":158,"type":21},{"date":265,"type":21},"2029-06-30",{"name":39,"class":40},2,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":16,"minAge":252,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":41},"100635526","clinical-and-subclinical-keratoconus-cohort-study-100635526","NCT07553832","Clinical and Subclinical Keratoconus Cohort Study","Inclusion criteria:\n\n1. Inclusion criteria for suspected keratoconus 1.1 Both eyes did not meet the diagnostic criteria for keratoconus, and the included eyes met the criteria 1.1.1 BCVA≥1.0 1.1.2 No obvious abnormal signs under slit lamp; 1.1.3 At least one abnormal corneal topography feature: abnormal anterior corneal surface (KISA\\>60%); Asymmetric collar with or without meridional tilt (I-S \\>1.4D); Abnormal increase of corneal curvature (Km\\>47.2D); The posterior surface of the cornea was abnormally elevated (PTE\\>11μm).\n\n   1.1.4 1.6≤BAD-D \\\u003C 2.6 in Pantacam. 1.2 Patients aged 4 years or older. 1.3 informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.\n2. Inclusion criteria for subclinical keratoconus:\n\n   2.1 The contralateral eye was diagnosed with keratoconus, and the included eye met the following criteria: 2.1.1 BCVA≥1.0 2.1.2 No obvious abnormal signs under slit lamp; 2.1.3 BAD-D \\\u003C 2.6 in Pantacam. 2.2 Age ≥ 4 years old. 2.3 informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.\n3. Keratoconus inclusion criteria:\n\n3.1 History of myopia and astigmatism, BCVA≤1.0 3.2 Slit-lamp examination reveals at least one sign: corneal thinning, conical protrusion, Vogts striae, Fleischers rings, or anterior stromal scarring.\n\n3.3 abnormal corneal topography features, such as asymmetric bow tie, subtemporal steeping, abnormal thickness distribution, and reduced minimum thickness, with BAD-D≥2.6 in Pantacam.\n\n3.4 Age ≥ 4 years old. 3.5 Informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.\n\nExclusion criteria:\n\n1. Patients with a history of ocular surgery and significant corneal scarring.\n2. Patients who could not understand or cooperate with the examination and follow-up.",{"count":275,"type":21},421,"The pathogenesis of keratoconus remains unclear, and its natural course has yet to be fully understood. For non-progressive patients and post-surgical cases, clinical management primarily involves follow-up observation, with significant challenges in visual rehabilitation. This study aims to establish a prospective keratoconus cohort to identify risk factors, natural progression, and the efficacy of interventions. Additionally, it seeks to explore changes in ocular biometric parameters and other pathophysiological characteristics in keratoconus patients, investigate the relationship between keratoconus and systemic diseases or comorbidities, and assess refractive interventions and visual rehabilitation strategies for keratoconus patients.",[278],"Keratoconus",{"date":280,"type":33},"2026-04-28",{"date":282,"type":21},"2026-09-01",{"date":284,"type":21},"2029-12-01",{"name":39,"class":40},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100602665","impact-of-capsular-tension-ring-on-intraocular-lens-position-in-retinitis-pigmentosa-cataract-patients-100602665","NCT07126470","Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients","Effect of Capsular Tension Ring Implantation on Postoperative IOL Position in Retinitis Pigmentosa Patients With Cataract: a Multi-center, Randomized, Self-controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of retinitis pigmentosa (RP).\n* Bilateral cataract meeting the indications for IOL implantation.\n* Willingness to participate in the study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* History of intraocular surgery.\n* Severe zonular weakness (e.g., zonular dialysis \\>90°, lens subluxation\u002Fdislocation)\n* Other ocular comorbidity: such as pseudoexfoliation syndrome, ocular trauma, corneal dystrophies, uveitis, etc.\n* Severe systemic diseases: such as severe hypertension, diabetes, heart disease, Alzheimer's, Parkinson, etc.",{"count":294,"type":21},88,[24],"This is a self-controlled randomized clinical trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) position in cataract patients with retinitis pigmentosa(RP). Each patient will receive CTR implantation in one eye, with the fellow eye serving as control. Postoperative outcomes, including visual acuity, IOL position, and postoperative complications will be compared between eyes.",[56,298],"Retinitis Pigmentosa (RP)",{"date":300,"type":33},"2026-04-23",{"date":302,"type":33},"2025-08-25",{"date":304,"type":21},"2027-08",{"name":39,"class":40},3,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":49,"sex":16,"minAge":314,"maxAge":17,"enrollmentInfo":315,"targetDuration":314,"studyType":52,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":41},"100635058","evaluation-of-a-county-based-eye-health-service-model-in-rural-chinese-children-100635058","NCT07547748","Evaluation of a County-Based Eye Health Service Model in Rural Chinese Children","Evaluation of a County-Based Eye Health Service Model for Preventing and Controlling Avoidable Visual Impairment in Rural Chinese Children","Inclusion Criteria:\n\n* Aged 3 to 18 years; Enrolled in schools within the study areas, including kindergartens, primary schools, junior high schools, and senior high schools, in Yangxi County, Jiexi County, Huidong County, and Yingde City of Guangdong Province, as well as Fengqing County of Yunnan Province, or are children and adolescents who are permanent residents within these jurisdictions.\n* Written informed consent has been provided by their legal guardians.\n* For children aged 8 years and older, assent from the child is also required.\n\nExclusion Criteria:\n\n* Presence of severe systemic diseases (such as severe congenital heart disease or intellectual developmental disorders) that preclude cooperation with ophthalmic examinations.\n* Refusal by the legal guardian to participate, or inability of the legal guardian to cooperate with scheduled follow-up visits.","3 Years",{"count":316,"type":21},20000,"This project proposes to conduct a prospective, multicenter registry study in rural China to evaluate, under real-world conditions, the implementation effectiveness of an integrated child eye health service model centered at the county level and coordinated across county, township, village, and school tiers. The target population will include all children and adolescents within participating counties, and the primary exposure will be the annual coverage and implementation intensity of this service model. The study will focus on its impact on clinical outcomes such as refractive error correction rates and referral rates following eye disease screening, while also examining annual trends in disparities in access to different eye care services. Through long-term and systematic observation, the project aims to clarify the sustained effects of this eye health service model on improving the management of pediatric eye diseases, enhancing visual function, and promoting health equity, thereby providing evidence-based support for optimizing the rural child eye care system in China.",[319,320,321],"Myopia","Strabismus","Eye Health","2026-04-16",{"date":300,"type":33},{"date":325,"type":33},"2025-01-01",{"date":327,"type":21},"2028-12-31",{"name":39,"class":40},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":41},"100530708","rct-on-intralesional-rituximab-injection-versus-isrt-in-ocular-adnexal-malt-lymphoma-100530708","NCT06190301","RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma","Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Randomized Controlled Trial","Inclusion criteria\n\n1. Age between 18 to 75 years old.\n2. Ocular adnexal MALT lymphoma with a comprehensive diagnosis based on pathology, clinical manifestations, and biological characteristics according to the WHO classification of tumors of hematopoietic and lymphoid tissues.\n3. Based on the TNM staging of ocular adnexal lymphoma, patients with stages T1-3 of ocular adnexal MALT lymphoma without involvement of intraconal compartment are included.\n4. Willing to participate the trial and sign the informed consent form.\n\nExclusion criteria\n\n1. Based on the TNM staging of ocular adnexal lymphoma (Table 1), patients staged as T2\u002FT3 with involvement of intraconal compartment and patients staged as T4.\n2. Patients who have previously received local or systemic radiation, chemotherapy, or drug treatment specifically for ocular adnexal MALT lymphoma.\n3. Presence of cataract and is anticipated to require surgical treatment within a certain period after enrollment; existing cataract affects visual field testing and fundoscopic examination; vision affected by cataract is \\\u003C20\u002F40.\n4. In addition to the need for treatment of ocular adnexal MALT lymphoma, there is a requirement for other ocular procedures (e.g., full-thickness corneal transplant or retinal surgery) or an anticipated need for another emergent ocular surgery.\n5. Complicated with other ocular diseases: including corneal abnormalities or existing corneal infections, iridocorneal endothelial syndrome, anterior segment dysgenesis, true microphthalmos, uveitis, glaucoma, ocular trauma, and retinal disorders such as central retinal vein occlusion, central retinal artery occlusion, retinal detachment, etc.\n6. The statue of HBV or HIV infection.\n7. Need for long-term use of local or systemic steroids.\n8. Patients already enrolled in other drug clinical trials.\n9. Pregnant or breastfeeding women.\n10. Serious systemic diseases: advanced cardiac disease, kidney disease, respiratory disease, or other malignant tumors, etc.\n11. Inability to understand the research content.\n\nIf both eyes of a patient meet the inclusion criteria, the right eye will be selected for participation in the study, while the left eye will receive the same treatment, but its data will not be included in this research. Each patient can have only one eye participating in the study. If both eyes of a patient meet the inclusion criteria and the patient is randomized to the ISRT group, the eye with the larger lesion or with more symptomatic disease is treated first, and in the case of well tolerability, the other eye is irradiated.","75 Years",{"count":338,"type":21},108,[24],"This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.",[342],"Primary Ocular Adnexal MALT Lymphoma","2026-04-14",{"date":162,"type":33},{"date":346,"type":33},"2023-12-20",{"date":348,"type":21},"2029-12-31",{"name":39,"class":40},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":16,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":267},"100611483","early-phase-1-the-safety-and-efficacy-of-zvs106e-in-the-treatment-of-irds-caused-by-biallelic-mutations-in-abca4-100611483","NCT07241169","The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4","A Preliminary Clinical Study on the Safety and Efficacy of the Gene Replacement Drug ZVS106e in the Treatment of Hereditary Retinal Degeneration (IRDs) Caused by ABCA4 Biallelic Mutations","ZVS106e","Inclusion Criteria:\n\n1. Age ≥8 years old;\n2. Patients diagnosed with hereditary retinal degeneration caused by ABCA4 biallelic mutations through genetic testing, and without other ophthalmic genetic diseases;\n3. The target eye must meet the following requirements: the best corrected visual acuity is 0.5 to 2.0 LogMAR (including 0.5 and 2.0 LogMAR, equivalent to the decimal visual acuity index up to 0.3);\n4. The subject and his or her spouse agree to take effective contraceptive measures during the trial period and for at least one year after administration.\n5. Voluntarily participate in clinical trials and sign informed consent forms, and be able to complete all trial processes as required by the protocol.\n\nExclusion Criteria:\n\n1. The researchers determined that the target eye currently has or has previously had other macular lesions such as retinal schisis or epiretinal membrane. Or have other eye diseases that may hinder the surgery or interfere with the interpretation of the study endpoint;\n2. Having received drug treatment that may affect the observation of the trial within the three months prior to screening;\n3. The target eye has undergone the following intraocular surgeries: retinal repositioning and vitrectomy;\n4. There are known eye\u002Fvisual diseases, disorders or lesions that cause or are related to vision loss, or whose related treatments or therapies are known to cause or are related to vision loss;\n5. Having suffered from a viral infectious disease that may affect the efficacy and safety evaluation of the investigational drug or having received an antiviral vaccine within one month prior to enrollment;\n6. Systemic medications that are currently in use or may be required to cause eye toxicity, such as psoralen, risselinic acid or tamoxifen, etc.\n7. Known to be allergic to the drugs planned to be used in the study;\n8. Suffering from poorly drug-controlled hypertension: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg;\n9. The following laboratory test abnormalities have clinical significance:\n\n   Liver function: Chronic liver disease, elevation of ALT or AST \\>2 times the upper limit of the normal value; Those with abnormal coagulation function (prothrombin time ≥ 3 seconds above the upper limit of the normal value, activated partial thromboplastin time ≥ 10 seconds above the upper limit of the normal value); Serum virological examination: Positive for active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis antibody;\n10. There is any past or current medical history that may affect the safety of the trial or the in vivo process of the drug, especially a history of diseases such as cardiovascular, liver, kidney, endocrine, digestive tract, lung, nervous, hematological, tumor, immune or metabolic disorders that the investigators consider to have clinical significance;\n11. Those who have participated in any clinical trials of drugs or medical devices within the three months prior to screening;\n12. Pregnant or lactating women; According to the researcher's judgment, those who are deemed unsuitable to participate in this clinical trial for other reasons","8 Years",{"count":360,"type":21},9,[362],"EARLY_PHASE1","To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.",[365],"Stargardt",[356],"2026-04-13",{"date":322,"type":33},{"date":370,"type":33},"2025-12-29",{"date":372,"type":21},"2028-12-30",{"name":39,"class":40},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":49,"sex":16,"minAge":314,"maxAge":18,"enrollmentInfo":380,"targetDuration":382,"studyType":52,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":41},"100634034","a-prospective-cohort-study-on-visual-function-and-psychological-conditions-before-and-after-surgery-for-congenital-ptosis-100634034","NCT07534436","A Prospective Cohort Study on Visual Function and Psychological Conditions Before and After Surgery for Congenital Ptosis","Inclusion Criteria:\n\n1. Unilateral or bilateral congenital ptosis, male or female;\n2. Age: 3-60 years old\n3. Informed consent, and voluntary signing of the informed consent form, in compliance with ethical norms\n\nExclusion Criteria:\n\n\\-",{"count":381,"type":21},73,"6 Months","The goal of this observational study is to learn about the 6-month effects of Levator Resection combined with Fascial Sheath Suspension surgery in patients who undergo this procedure to treat congenital ptosis. The main questions it aims to answer are:\n\nDoes this combined surgery improve best-corrected visual acuity, stereopsis, and other visual function indicators in patients with congenital ptosis within 6 months after the operation?\n\nDoes this surgery lead to an improvement in patient-reported quality of life during the same period?\n\nPatients already scheduled to undergo this combined surgery as part of their regular medical care for congenital ptosis will complete a series of standardized ophthalmological examinations and a quality of life questionnaire before surgery and at 1, 3, and 6 months post-operation.",[385],"Ptosis","2026-04-09",{"date":322,"type":33},{"date":389,"type":33},"2025-06-01",{"date":391,"type":21},"2026-09-30",{"name":39,"class":40},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":399,"targetDuration":4,"studyType":22,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":4},"100633287","effect-of-behavioral-intervention-baduanjin-alone-or-laughter-exercise-plus-artificial-tears-versus-artificial-tear-on-dry-eye-disease-a-randomised-controlled-trial-100633287","NCT07524725","Effect of Behavioral Intervention (Baduanjin Alone or Laughter Exercise Plus Artificial Tears) Versus Artificial Tear on Dry Eye Disease: a Randomised Controlled Trial","Inclusion Criteria:\n\n* ≥18 TO ≤45 years of age, any sex.\n* Meet the dry eye diagnostic criteria of the DEWS international consensus, and show both of the following two conditions: OSDI score between 18 and 80; NIBUT (Non-invasive tear break-up time) \\\u003C 8 seconds\n* Best corrected visual acuity ≥ 0.5(10\u002F20) (in each eye).\n* Intraocular pressure between 5 and 21 mmHg (in each eye).\n* Women of childbearing potential must agree to use safe contraception during the study.\n* Willingness\u002Fability to return for all study visits and to follow instructions from the study investigator and their staff.\n* Voluntary participation and signing of the informed consent form approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* NEI corneal fluorescein staining score \\> 5 (in either eye).\n* Wore contact lenses within the past 14 days and cannot commit to not wearing them during the study period (3 months) (in either eye).\n* Received refractive surgery (LASIK, SMILE) or other ocular surgery, or had ocular trauma within the past 12 months (in either eye).\n* Had acute allergic conjunctivitis, infection, or ocular surface inflammation within the past 3 months (in either eye).\n* Eyelid abnormalities that affect eyelid function, such as nystagmus, blepharospasm, ectropion, entropion, or severe trichiasis (in either eye).\n* Previously diagnosed with glaucoma and received medical or surgical treatment (in either eye).\n* Currently receiving other ophthalmic or systemic treatments that may affect the tear film.\n* Allergy to fluorescein sodium.\n* Have a serious health condition that may limit their ability to participate.\n* Pregnant, breastfeeding, or planning to become pregnant.\n* Diagnosed with neurological or psychiatric disorders (e.g., severe anxiety, depression, or severe sleep disorder).\n* Have difficulty with physical movement.\n* Previous experience with traditional exercise such as Baduanjin.\n* Previous experience with laughter exercise.",{"count":400,"type":21},540,[24],"The goal of this clinical trial is to compare the effect of behavioral intervention (Baduanjin alone or laughter exercise plus artificial tears) versus artificial tears in patients with dry eye disease.\n\nThe main questions it aims to answer are:\n\n* Does the Baduanjin improve the Ocular Surface Disease Index score of patients with dry eye disease?\n* Does the laughter exercise plus artificial tears improve the Ocular Surface Disease Index score of patients with dry eye disease?\n\nResearchers will compare behavioral intervention (Baduanjin alone or laughter exercise plus artificial tears) versus artificial tears to see if behavioral intervention works to treat dry eye disease.\n\nParticipants will：\n\n* Do the Baduanjin 5 times per week, or do laughter exercise plus artifical tears 4 times per day, or use artificial tears alone 4 times per day for 12 weeks\n* Visit the clinic once right before the intervention and the 4, 8, 12, 16, 24, 36, and 48 weeks after starting the intervention for checkups and tests\n* Use the app developed by our study to record the behavioral intervention and\u002For use of eye drops.",[27],"2026-04-05",{"date":367,"type":33},{"date":407,"type":21},"2027-01-01",{"date":409,"type":21},"2033-12-31",{"name":39,"class":40},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100632317","the-impact-of-a-miss-is-as-good-as-a-mile-is-compensation-necessary-for-minimal-ocular-deviation-in-myopic-laser-surgery-100632317","NCT07512115","The Impact of 'A Miss Is as Good as a Mile': Is Compensation Necessary for Minimal Ocular Deviation in Myopic Laser Surgery?","Effect of Centration Compensation on Visual Quality in VisuMax 800 SMILE for Small Kappa Angles: A Randomized Trial","Inclusion Criteria:\n\n1. Patients aged 18 to 40 years with myopia or myopic astigmatism and stable refraction for \\>=1 year, whose refractive errors fall within the treatable range of and meet the indications for SMILE surgery.\n2. Normal corneal morphology and corneal thickness meeting surgical requirements.\n3. Preoperative corrected distance visual acuity (CDVA) \\>= 1.0.\n4. Preoperative synthetic Kappa angle offset measured \\>= 0.10 mm and \\\u003C 0.20 mm.\n5. Voluntarily agree to undergo SMILE surgery on the VISUMAX 800 platform, understand the randomization scheme, and provide signed informed consent.\n\nExclusion Criteria:\n\n1. History of prior ocular surgery, significant ocular trauma, or presence of corneal or ocular diseases that may affect the safety of refractive surgery.\n2. Severe systemic diseases that may affect ocular healing or surgical safety.\n3. Females who are pregnant or lactating.\n4. Inability to cooperate as required to complete the procedure or follow-up visits.","40 Years",{"count":420,"type":21},224,[24],"The goal of this clinical trial is to evaluate the effect of intraoperative kappa-angle compensation on postoperative visual quality in patients undergoing small incision lenticule extraction (SMILE) using the VisuMax 800 platform. The study will enroll patients with myopia and a kappa-angle offset \\\u003C 0.2 mm.\n\nThe main questions it aims to answer are:\n\nDoes intraoperative kappa-angle compensation reduce postoperative higher-order aberrations after SMILE? Does kappa-angle compensation improve postoperative visual quality and refractive outcomes compared with no compensation?\n\nResearchers will compare SMILE with intraoperative kappa-angle compensation to SMILE without compensation to determine whether compensation leads to better optical quality and visual performance.\n\nParticipants will:\n\nUndergo SMILE surgery with or without intraoperative kappa-angle compensation Complete scheduled postoperative examinations at 1 week, 1 month, 3 months, and 6 months after surgery Receive measurements of visual acuity, refraction, higher-order aberrations, contrast sensitivity, and safety outcomes",[319,424],"Refractive Ametropia",[426,427,428,429,430,431],"myopia","SMILE","Refractive Surgery","Randomized Clinical Trial","Angle Kappa","VisuMax 800","2026-03-31",{"date":434,"type":33},"2026-04-06",{"date":436,"type":21},"2026-04-01",{"date":438,"type":21},"2027-05-30",{"name":39,"class":40},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":418,"enrollmentInfo":446,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":455,"locationsCount":4},"100632316","comparison-of-low--versus-high-level-angle-kappa-compensation-strategies-in-smile-using-the-visumax-800-a-randomized-clinical-trial-100632316","NCT07512102","Comparison of Low- Versus High-Level Angle Kappa Compensation Strategies in SMILE Using the VisuMax 800: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age range: 18 - 40 years old. Patients with stable refractive status for \\>= 1 year, having myopia or myopic astigmatism, with refractive power within the range of SMILE procedure.\n2. Normal corneal morphology and corneal thickness meeting the surgical requirements.\n3. Best corrected visual acuity (CDVA) before surgery \\>= 1.0.\n4. The kappa angle-related offset coordinates (x, y) obtained before surgery, with the absolute value of either \\|x\\| or \\|yl\\| of any eye \\>= 0.20mm.\n5. Voluntary to undergo SMILE surgery on the VISUMAX800 platform, understanding the random grouping scheme and signing the informed consent form.\n\nExclusion Criteria:\n\n1. History of prior ocular surgery, significant ocular trauma, or presence of corneal or ocular diseases that may affect the safety of refractive surgery.\n2. Severe systemic diseases that may affect ocular healing or surgical safety.\n3. Females who are pregnant or lactating.\n4. Inability to cooperate as required to complete the procedure or follow-up visits.",{"count":447,"type":21},100,[24],"The goal of this clinical trial is to compare two intraoperative kappa-angle compensation strategies during small incision lenticule extraction (SMILE) using the VisuMax 800 platform in patients with relatively large kappa-angle offsets.\n\nAngle kappa represents the difference between the visual axis and the pupil center. In patients with a large offset, pupil-centered treatment may lead to decentration of the optical zone, which can induce higher-order aberrations and affect postoperative visual quality. The VisuMax 800 system allows intraoperative adjustment of the treatment center based on the measured offset, making different compensation strategies possible.\n\nThe main questions this study aims to answer are:\n\nDoes low kappa-angle compensation (50%) result in lower postoperative higher-order aberrations than high compensation (100%)? Does the compensation strategy influence visual acuity, refractive outcomes, contrast sensitivity, and subjective visual quality after SMILE? Are the measurements obtained from different diagnostic devices consistent when evaluating kappa-related parameters?\n\nResearchers will compare SMILE with low compensation to SMILE with high compensation to determine which strategy provides better optical quality and visual performance.\n\nParticipants will:\n\nUndergo SMILE surgery using either low or high kappa-angle compensation Complete scheduled postoperative examinations at 1 month, 3 months, and 6 months Receive measurements of visual acuity, refraction, higher-order aberrations, contrast sensitivity, and patient-reported visual outcomes Be monitored for safety outcomes and adverse events during follow-up",[319,424],[426,427,428,429,430,431],{"date":434,"type":33},{"date":436,"type":21},{"date":438,"type":21},{"name":39,"class":40},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":16,"minAge":418,"maxAge":462,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":469,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100632315","comparison-of-presbyond-laser-blended-vision-and-conventional-monovision-lasik-in-individuals-with-presbyopia-a-randomized-clinical-study-100632315","NCT07512089","Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomized Clinical Study","Inclusion Criteria:\n\n* Adults aged 40 to 55 years with presbyopia\n* Suitable candidates for LASIK surgery based on clinical evaluation\n* Stable refractive status for at least 1 year\n* Best corrected distance visual acuity within normal range\n* Willing and able to provide written informed consent\n* Willing to comply with study visits and follow-up\n\nExclusion Criteria:\n\n* Previous ocular surgery\n* Corneal disease or abnormal corneal condition that may affect safety\n* Significant ocular disease affecting visual function\n* Severe dry eye or other ocular surface disorders\n* Systemic disease that may affect study participation\n* Inability to tolerate monovision or anisometropia\n* Any condition that the investigator considers unsuitable for the study","55 Years",{"count":447,"type":21},[24],"The goal of this clinical trial is to learn if laser blended vision (LBV) works better than traditional monovision LASIK to correct presbyopia in adults aged 40 to 55 years. Presbyopia is an age-related condition that makes it hard to see things up close. The study will also evaluate the safety of both procedures.\n\nThe main questions it aims to answer are:\n\nDoes LBV improve distance, intermediate, and near vision at the same time after surgery? Is LBV as safe as traditional monovision LASIK?\n\nResearchers will compare laser blended vision to traditional monovision LASIK to see if LBV provides better overall vision after surgery.\n\nParticipants will:\n\nBe randomly assigned to receive either laser blended vision or traditional monovision LASIK Have standard eye examinations before surgery Undergo LASIK surgery using the assigned method Return for follow-up visits at 1 week, 1 month, 3 months, and 6 months after surgery Complete vision tests and questionnaires about visual quality and satisfaction",[467,468],"Presbyopia","Refractive Error",[467,470,471,472,428,429],"LASIK","Laser Blended Vision","Monovision",{"date":434,"type":33},{"date":436,"type":21},{"date":476,"type":21},"2028-06-30",{"name":39,"class":40},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":306},"100613631","phase-4-efficacy-and-safety-of-anrikefon-for-postoperative-analgesia-in-ophthalmic-surgery-100613631","NCT07269106","Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery","Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery: A Multicenter, Randomized, Parallel-Control, Non-Inferiority Trial","Inclusion Criteria:\n\n* Scheduled for ophthalmic surgery under general anesthesia.\n* Aged 18 to 70 years.\n* With American Society of Anesthesiologists (ASA) physical status I to III.\n* Body mass index (BMI) between 18 and 30 kg\u002Fm²\n* Agree to participate in the trial and provide written informed consent.\n\nExclusion Criteria:\n\n* History of cardiovascular or cerebrovascular events within the past 6 months, including unstable angina, ischemic myocardial infarction, or heart failure; or current presence of uncontrolled hypertension (\\>180\u002F110 mmHg), aneurysm, or severe cardiac arrhythmia.\n* Severe respiratory diseases such as pulmonary fibrosis, severe pulmonary abscess, cor pulmonale, or advanced chronic obstructive pulmonary disease (COPD).\n* Significant neurological disorders such as brain injury or seizures, as well as severe psychiatric illnesses.\n* Known allergy to kappa opioid receptor agonists or to general anesthetic agents used in this study.\n* Current peptic ulcer disease, gastrointestinal bleeding, or known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs), such as flurbiprofen axetil or paracetamol.\n* Prior use of opioid or non-opioid analgesics, with the last administration occurring within five half-life periods of the drug.\n* Continuous use of opioid analgesics for more than 10 days within the 3 months prior to screening.\n* Use of drugs with unknown half-life periods that may affect analgesic efficacy within 14 days before randomization.\n* History of major surgery within the past 3 months that may interfere with postoperative pain assessment.","70 Years",{"count":487,"type":21},204,[226],"The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon.\n\nThe main questions it aims to answer are:\n\n* Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery?\n* Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine?\n* Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients.\n\nParticipants will:\n\n* Receive either an intravenous dose of Anrikefon or nalbuphine during surgery.\n* Be monitored for pain scores, side effects, and recovery parameters after surgery.\n* Complete follow-up assessments.",[491,492,493],"Ophthalmic Surgery","Postoperative Pain Management","Opioid Analgesia",{"date":436,"type":33},{"date":496,"type":33},"2026-01-22",{"date":498,"type":21},"2027-12-31",{"name":39,"class":40},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":16,"minAge":358,"maxAge":222,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":512,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":41},"100613267","evaluation-of-the-safety-and-efficacy-of-the-ddc-dual-control-technology-spectacle-lenses-in-delaying-the-progression-of-myopia-a-randomized-controlled-trial-100613267","NCT07264361","Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 6 and 14 years;\n* Cycloplegic spherical equivalent refraction between -1.50 D and -5.00 D with astigmatism ≥ -1.50 D in both eyes;\n* Absolute interocular difference in spherical equivalent refraction ≤ 1.50 D;\n* Binocular best-corrected visual acuity ≥ 1.0;\n* Intraocular pressure between 10 and 21 mmHg in both eyes;\n* Volunteer to participate in this clinical trial with signature of the informed consent form.\n\nExclusion Criteria:\n\n* History of eye injury or intraocular surgery or ocular trauma;\n* Clinically abnormal slit-lamp findings;\n* Abnormal fundus examination;\n* Presence of ocular diseases such as cataract, glaucoma, fundus pathology, ocular trauma, manifest strabismus, or any other condition affecting visual function;\n* Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses);\n* Participation in a drug clinical trial within 3 months or a device clinical trial within 1 month prior to enrollment;\n* Participation in any myopia control clinical trial within the past 3 months and a history of myopia control interventions (e.g., orthokeratology, atropine);\n* Only one eye meeting the inclusion criteria;\n* Inability to attend regular ophthalmic examinations.",{"count":507,"type":21},316,[24],"The burden of myopia among Chinese children and adolescents is severe and trending toward younger ages, making control of myopia progression a public health priority. Current mainstream strategies include optical interventions, pharmacologic therapy, and environmental measures. Among these strategies, spectacle designs based on optical defocus-such as defocus-incorporated multiple-segment (DIMS) lenses-have demonstrated efficacy; however, the effect of such designs may attenuate over time because of \"defocus adaptation.\" To address this limitation, D.D.C dual-control spectacles employ a densely staggered microlens layout, a gradient-defocus architecture, and an added peripheral \"fogging zone\" to disrupt the spatial distribution of defocus cues and reduce contrast, thereby delaying adaptation and enhancing myopia-control efficacy.\n\nThe present study therefore proposes a 24-month prospective randomized controlled trial in Guangzhou, enrolling eligible myopic adolescents. The trial will first compare 12-month outcomes between D.D.C-A lenses and single-vision lenses, followed by a crossover and alternating-wear phase, to systematically evaluate the safety and efficacy of the D.D.C technology in slowing myopia progression.",[511],"Myopia, Progressive",[513,514],"Defocus diffusion composite technology","Myopia control","2026-03-11",{"date":517,"type":33},"2026-03-12",{"date":519,"type":21},"2026-03-30",{"date":521,"type":21},"2027-12-20",{"name":39,"class":40},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":16,"minAge":252,"maxAge":17,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":41},"100627299","effect-of-different-needle-insertion-positions-on-the-clinical-outcomes-of-yamane-technique-100627299","NCT07446829","Effect of Different Needle Insertion Positions on the Clinical Outcomes of YAMANE Technique","Effect of Different Needle Insertion Positions on the Clinical Outcomes of YAMANE Technique for Intrascleral Intraocular Lens Fixation: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 4-18 years (regardless of gender) who meet the indications for YAMANE technique.\n2. Patients who can complete a follow-up period of at least 3 months after surgery.\n3. Patients or their legal guardians who provide informed consent to participate in this study.\n\nExclusion Criteria:\n\n1. Patients with concurent secondary qlaucoma, retinal detachment, strabismus, or other relevant ocular complications (excluding refractive errors).\n2. Patients participating in other trials that may affect the results of this study.",{"count":531,"type":21},54,[24],"This is a single-blind, single-center, parallel-group randomized controlled trial with the following objectives: First, researchers aim to compare the clinical efficacy of 2mm and 2.5mm post-limbal needle insertion in YAMANE technique for patients with congenital ectopia lentis. Second, the goal is to investigate the mean absolute refractive prediction error, IOL tilt and decentration, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), and corneal endothelial cell count at 3 months postoperatively. Third, it intends to explore the incidence of postoperative complications of the two needle insertion positions in this specific surgical method. Finally, this study aims to provide evidence for ophthalmic clinical practice, explore the optimal needle insertion point, and offer more precise and safe surgical plans for patients requiring sutureless transscleral IOL fixation.",[535],"Congenital Ectopia Lentis","2026-03-02",{"date":538,"type":33},"2026-03-04",{"date":540,"type":21},"2026-02-28",{"date":542,"type":21},"2027-08-30",{"name":39,"class":40},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":16,"minAge":150,"maxAge":151,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":41},"100624239","comparison-of-early-postoperative-visual-acuity-between-intracapsular-and-supracapsular-phacoemulsification-a-randomized-controlled-clinical-trial-100624239","NCT07407049","Comparison of Early Postoperative Visual Acuity Between Intracapsular and Supracapsular Phacoemulsification: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 50 years and ≤ 90 years\n* Able to cooperate with preoperative examinations\n* At least one eye meets the study eye criteria\n* Has the capacity and willingness to provide informed consent\n* Age-related cataract\n* Nuclear opacity (N) graded ≥4 according to the Lens Opacities Classification System III (LOCS III)\n* Scheduled for phacoemulsification with intraocular lens implantation\n* Pupil size ≥6 mm after dilation\n* Corneal endothelial cell density ≥1500 cells\u002Fmm²\n\nExclusion Criteria:\n\n* Considered unsuitable by the investigator for participation in this clinical trial for other reasons (e.g., unstable systemic condition, uncontrolled blood pressure\u002Fblood glucose, severe cardiovascular disease, renal disease, etc.)\n* Blood pressure \\> 180\u002F110 mmHg (systolic \\>180 mmHg or diastolic \\>110 mmHg). Patients may be considered for inclusion if blood pressure can be controlled below these thresholds with medication.\n* History of myocardial infarction or other cardiac disease requiring hospitalization, cerebral infarction, transient ischemic attack, or acute heart failure within 4 months prior to enrollment.\n* Women with childbearing potential (i.e., currently pregnant, breastfeeding, or planning to become pregnant within the next 2 years). Women of childbearing potential should be asked about the possibility of pregnancy, and the investigator will determine when a pregnancy test is necessary.\n* Currently participating in another clinical trial\n* History of ocular trauma or surgery\n* Presence of other ocular diseases (e.g., glaucoma, diabetic retinopathy)\n* Other ocular factors that may complicate surgery (e.g., small pupil, shallow anterior chamber)",{"count":551,"type":21},128,[24],"Cataracts are the leading cause of blindness worldwide, and phacoemulsification combined with intraocular lens implantation has become the most mainstream surgical approach. With advancements in surgical techniques and equipment, this procedure has evolved from a simple vision-restoring surgery into the era of refractive surgery. Patients now have higher expectations for postoperative visual quality, particularly the recovery of early vision, which directly impacts their satisfaction. Intraoperative surgical details have a direct influence on postoperative visual acuity.\n\nThanks to intraoperative optical coherence tomography (iOCT) technology, surgeons have gradually recognized that factors such as surgical incisions and intraoperative anterior chamber collapse can affect the survival of corneal endothelial cells after surgery, which is directly related to early postoperative vision and patient satisfaction. Swept-source intraoperative OCT (SS-iOCT) has further improved imaging range and clarity, helping us discover that the depth of intraoperative ultrasound energy use (such as cumulative dissipated energy) correlates with postoperative corneal endothelial cell loss. This suggests that compared to performing phacoemulsification at the capsular opening plane or in the anterior chamber, intracapsular phacoemulsification may reduce postoperative corneal endothelial cell loss, potentially leading to better early postoperative vision, which is crucial for patient satisfaction. However, evidence is still lacking.\n\nTherefore, this study aims to compare the effects of intracapsular versus extracapsular phacoemulsification on early postoperative vision, as well as long-term visual acuity, corneal endothelial cells, corneal changes, and the incidence of intraoperative and postoperative complications.",[56],"2026-02-05",{"date":557,"type":33},"2026-02-12",{"date":559,"type":21},"2026-02-24",{"date":561,"type":21},"2026-12-31",{"name":39,"class":40},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":49,"sex":16,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":582,"locationsCount":4},"100523667","effect-of-carotenoids-supplementation-on-visual-function-in-chinese-subjects-100523667","NCT06098677","Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects","Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects Free of Retinal Disease: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Chinese subjects\n* Age 35 years or above\n* Monocular BCVA of 6\u002F6 or better\n* No more than +\u002F- 5 diopters spherical equivalence of refraction\n* No previous consumption of supplements containing macular carotenoids (L, Z and\u002For MZ) within the last 12 months\n* Without severe retinal diseases (eg. retinal detachment, glaucoma, macular hole, idiopathic epiretinal membrane, retinitis pigmentosa, and age-related macular degeneration (assessed by experienced ophthalmologists during ocular examination)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* With diagnosed diabetes\n* With severe systemic disease which affects physical mobility and successful follow-up\n* Contrast sensitivity at a spatial density of 6 cpd ≤ 1.5 % at baseline in the eye with better visual acuity\n* Subjects who plan to receive cataract surgery within the next year\n* Subjects who are unable to cooperate with the examinations during follow-ups, such as those who suffer from other serious systemic diseases or mental abnormalities\n* History of intraocular surgery (eg. cataract surgery, vitrectomy and retinal laser photocoagulation)","35 Years",{"count":572,"type":21},220,[24],"The macula is a pigmented area at the center of the retina, and responsible for the central, high-resolution color vision. Age-related macular degeneration (AMD) is a disease of the macula and is the leading cause of irreversible vision impairment and blindness worldwide. The yellow pigment at the macula is referred to as macular pigment. There is now strong evidence showing that macular pigment (MP), which is composed of the dietary carotenoids lutein (L), meso-zeaxanthin (MZ), and zeaxanthin (Z) is protective against AMD and vision loss. MP is a powerful antioxidant and also filters short-wavelength (blue) light at the macula. The AREDS2 study concluded that supplementation of L and Z is beneficial for patients with non-advanced age-related macular degeneration (AMD). The CREST and other studies had reported that dietary supplementation of these carotenoids could enhance contrast sensitivity among the Caucasian population, whereas little information is known about the effect of dietary supplementation of carotenoids on contrast sensitivity among Chinese. Thus in this study, we aim to investigate whether supplementation of a formulation containing 10 mg L, 10 mg MZ, and 2mg Z on contrast sensitivity in Chinese subjects free of retinal disease. This study is a single-center, double-blinded, placebo-controlled, randomized clinical trial conducted at Zhongshan Ophthalmic Center (ZOC), Sun Yat-sen University, Guangzhou, China. Participants in the intervention group received oral supplementation of 10 mg L, 10 mg MZ, and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Participants in the control group receive one soft gel capsule of placebo oil per day. The intervention and placebo supplements are identical in external appearance, and the two treatments are therefore indistinguishable from each other. The duration of the study intervention is 12 months, and study visits are conducted at baseline, 3 months, 6 months, and 12 months. The primary outcome measure is the change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over the study course: Y=CS4-CS1, where CS1 is CS at 6 cpd at baseline, CS4 is the CS at 6cpd at the 12-month follow-up. The secondary outcomes of this study include CS at other cpds and at other study visits, best-corrected visual acuity, subjective visual function, and skin carotenoid levels at each study visit.",[576],"Vision Disorders","2026-01-21",{"date":579,"type":33},"2026-01-23",{"date":241,"type":21},{"date":498,"type":21},{"name":39,"class":40},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":16,"minAge":252,"maxAge":17,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":41},"100612343","influence-of-different-needle-insertion-positions-on-the-clinical-efficacy-of-suture-fixated-transscleral-iol-implantation-without-knots-100612343","NCT07252349","Influence of Different Needle Insertion Positions on the Clinical Efficacy of Suture-Fixated Transscleral IOL Implantation Without Knots","Influence of Different Needle Insertion Positions on the Clinical Efficacy of Suture-Fixated Transscleral IOL Implantation Without Knots: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 4-18 years (regardless of gender) who meet the indications for transscleral suture-fixated intraocular lens implantation\n2. Patients who can complete a follow-up period of at least 3 months after surgery;\n3. Patients or their legal guardians who provide informed consent to participate in this study.\n\nExclusion Criteria:\n\n1. Patients with concurent secondary qlaucoma, retinal detachment, strabismus, or other relevant ocular complications (excludingrefractive errors);\n2. Patients participating in other trials that may affect the results of this study.",{"count":531,"type":21},[24],"This is a single-blind, single-center, parallel-group randomized controlled trial with the following objectives: First, researchers aim to compare the clinical efficacy of 2mm and 2.5mm post-limbal needle insertion in sutureless transscleral IOL fixation for patients with congenital ectopia lentis. Second, the goal is to investigate the mean absolute refractive prediction error, IOL tilt and decentration, uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), and corneal endothelial cell count at 3 months postoperatively. Third, it intends to explore the incidence of postoperative complications of the two needle insertion positions in this specific surgical method. Finally, this study aims to provide evidence for ophthalmic clinical practice, explore the optimal needle insertion point, and offer more precise and safe surgical plans for patients requiring sutureless transscleral IOL fixation.",[535],"2025-12-11",{"date":596,"type":33},"2025-12-18",{"date":598,"type":21},"2025-12-25",{"date":600,"type":21},"2027-08-31",{"name":39,"class":40},""]